ATE360441T1 - Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen - Google Patents
Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmenInfo
- Publication number
- ATE360441T1 ATE360441T1 AT02768574T AT02768574T ATE360441T1 AT E360441 T1 ATE360441 T1 AT E360441T1 AT 02768574 T AT02768574 T AT 02768574T AT 02768574 T AT02768574 T AT 02768574T AT E360441 T1 ATE360441 T1 AT E360441T1
- Authority
- AT
- Austria
- Prior art keywords
- bind
- formation
- inhibiting
- inhibitors
- complement inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31313701P | 2001-08-17 | 2001-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE360441T1 true ATE360441T1 (de) | 2007-05-15 |
Family
ID=23214536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02768574T ATE360441T1 (de) | 2001-08-17 | 2002-08-17 | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US7432356B2 (de) |
| EP (1) | EP1425042B2 (de) |
| JP (2) | JP4958387B2 (de) |
| CN (2) | CN100391537C (de) |
| AT (1) | ATE360441T1 (de) |
| AU (1) | AU2002331601B2 (de) |
| BR (1) | BRPI0211953B8 (de) |
| CA (1) | CA2457461C (de) |
| DE (1) | DE60219801T3 (de) |
| ES (1) | ES2283594T5 (de) |
| MX (2) | MXPA04001301A (de) |
| PT (1) | PT1425042E (de) |
| WO (1) | WO2003015819A1 (de) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001301A (es) * | 2001-08-17 | 2004-07-08 | Tanox Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
| MXPA05005909A (es) | 2002-12-02 | 2005-08-26 | Resistentia Pharmaceuticals Ab | Metodos y materiales para el tratamiento de condiciones inflamatorias usando un polipeptido que contiene un segmento aminoacido propio cs y un segmento aminoacido no propio. |
| EP2266606B1 (de) * | 2003-05-15 | 2014-09-10 | Genentech, Inc. | Verfahren und Zubereitungen zur Prävention und Behandlung von Blutvergiftung |
| EP2338511A3 (de) | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Verlängerung der Überlebungszeit eines Allografts durch Hemmung der Komplementsaktivität |
| WO2006093053A1 (ja) | 2005-03-02 | 2006-09-08 | Astellas Pharma Inc. | ヒストンデアセチラーゼ阻害剤の新規pdマーカー |
| JP2008543810A (ja) * | 2005-06-14 | 2008-12-04 | サイトス バイオテクノロジー アーゲー | 抗原コンジュゲート及びその使用 |
| US20070292421A1 (en) * | 2005-07-28 | 2007-12-20 | Feinberg Bruce B | Method for treating preeclampsia |
| DK2500030T4 (en) * | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| BRPI0708424A2 (pt) | 2006-03-02 | 2011-05-31 | Alexion Pharma Inc | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP4793360A2 (de) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur kontrolle der blut-pharmazeutizität von antikörpern |
| ZA200900954B (en) * | 2006-08-22 | 2010-05-26 | G2 Inflammation Pty Ltd | Ant-C5aR antibodies with improved properties |
| WO2008030505A2 (en) | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CN106084055A (zh) * | 2006-11-02 | 2016-11-09 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| EP3127921A1 (de) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur modifizierung eines isoelektrischen punkts eines antikörpers über aminosäuresubstition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
| EP2327725A1 (de) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a-bindende Teile mit hoher Blockieraktivität |
| AU2011245117B2 (en) | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| EP2468295A1 (de) | 2010-12-21 | 2012-06-27 | Affiris AG | Impfstoffe basierend auf Komplementprotein C5a Peptide |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| US9133269B2 (en) | 2012-08-24 | 2015-09-15 | Anaptysbio, Inc. | Humanized antibodies directed against complement protein C5 |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| US20140335546A1 (en) * | 2013-05-10 | 2014-11-13 | G J Carroll Pty Ltd | Devices and Methods for Determining the Risk of Developing a Serious Infection |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| WO2015028558A1 (en) * | 2013-08-28 | 2015-03-05 | Swedish Orphan Biovitrum Ab (Publ) | Stable polypeptides binding to human complement c5 |
| US9982022B2 (en) | 2013-08-28 | 2018-05-29 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EA201691481A1 (ru) * | 2014-03-20 | 2017-02-28 | Инфларкс Гмбх | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ |
| SG11201608868PA (en) | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト製造における方法及び中間体 |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| US20180016327A1 (en) | 2015-01-22 | 2018-01-18 | Chugai Seiyaku Kabushiki Kaisha | A Combination of Two or More Anti-C5 Antibodies and Methods of Use |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
| TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック, インコーポレイテッド | 抗d因子抗体変異体コンジュゲート及びその使用 |
| TW201730211A (zh) | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| CN108401431B (zh) | 2015-12-18 | 2022-01-25 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| SG11201805828YA (en) | 2016-01-14 | 2018-08-30 | Chemocentryx Inc | Method of treating c3 glomerulopathy |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| SG10201800265UA (en) | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| TWI828672B (zh) | 2017-01-31 | 2024-01-11 | 日商中外製藥股份有限公司 | 用於治療或預防c5相關疾病的醫藥組合物以及治療或預防c5相關疾病的方法 |
| EP3592386A4 (de) | 2017-03-06 | 2021-01-13 | The Trustees Of The University Of Pennsylvania | Anti-c5-antikörper und verwendungen davon |
| MX2019011252A (es) * | 2017-03-23 | 2020-01-23 | Univ Pennsylvania | Anticuerpos anti-c5a y usos de los mismos. |
| JP7161534B2 (ja) | 2017-11-29 | 2022-10-26 | エフ.ホフマン-ラ ロシュ アーゲー | 標的による干渉が抑制された抗薬物抗体アッセイ |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| MX2021000516A (es) | 2018-08-01 | 2021-04-12 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. |
| CN113038967B (zh) | 2018-09-06 | 2026-07-14 | 宾夕法尼亚大学理事会 | 人源化抗c5抗体及其用途 |
| EP4003409A1 (de) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosierungs- und verabreichungsschema zur behandlung oder vorbeugung von c5-bedingten krankheiten durch verwendung des anti-c5-antikörpers crovalimab |
| CN114466660A (zh) | 2019-07-31 | 2022-05-10 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| AU2020438234A1 (en) | 2020-03-27 | 2022-09-29 | Inflarx Gmbh | Inhibitors of C5a for the treatment of corona virus infection |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗c5a抗體 |
| KR102836238B1 (ko) | 2020-06-16 | 2025-07-18 | 에프. 호프만-라 로슈 아게 | 샘플에서 항체의 유리 항원 측정 방법 |
| JP7494413B2 (ja) * | 2020-07-15 | 2024-06-04 | ビオシオン インコーポレイテッド | C5に結合する抗体及びその用途 |
| WO2023050233A1 (en) * | 2021-09-29 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5a antibodies and uses thereof |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| DE3785967T2 (de) * | 1986-04-28 | 1993-12-02 | Cetus Corp | Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung. |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
| AU2191795A (en) * | 1994-03-23 | 1995-10-09 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5562904A (en) | 1994-07-21 | 1996-10-08 | Alexion Pharmaceuticals, Inc. | Retroviral transduction of cells using soluble complement inhibitors |
| AU3729295A (en) * | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US5572904A (en) * | 1995-01-05 | 1996-11-12 | Minculescu; Mihai C. | Oscillation lever arm engine |
| US6673346B1 (en) † | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
| MXPA04001301A (es) * | 2001-08-17 | 2004-07-08 | Tanox Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
-
2002
- 2002-08-17 MX MXPA04001301A patent/MXPA04001301A/es active IP Right Grant
- 2002-08-17 EP EP02768574.2A patent/EP1425042B2/de not_active Expired - Lifetime
- 2002-08-17 BR BRPI0211953-6 patent/BRPI0211953B8/pt not_active IP Right Cessation
- 2002-08-17 CA CA2457461A patent/CA2457461C/en not_active Expired - Fee Related
- 2002-08-17 CN CNB028161025A patent/CN100391537C/zh not_active Expired - Fee Related
- 2002-08-17 JP JP2003520777A patent/JP4958387B2/ja not_active Expired - Lifetime
- 2002-08-17 WO PCT/US2002/026074 patent/WO2003015819A1/en not_active Ceased
- 2002-08-17 CN CN200810091622.4A patent/CN101387646B/zh not_active Expired - Fee Related
- 2002-08-17 US US10/222,464 patent/US7432356B2/en not_active Expired - Fee Related
- 2002-08-17 DE DE60219801.1T patent/DE60219801T3/de not_active Expired - Lifetime
- 2002-08-17 MX MX2015001193A patent/MX342385B/es unknown
- 2002-08-17 AT AT02768574T patent/ATE360441T1/de active
- 2002-08-17 ES ES02768574.2T patent/ES2283594T5/es not_active Expired - Lifetime
- 2002-08-17 AU AU2002331601A patent/AU2002331601B2/en not_active Ceased
- 2002-08-17 PT PT02768574T patent/PT1425042E/pt unknown
-
2008
- 2008-01-24 US US12/011,058 patent/US8206716B2/en not_active Expired - Fee Related
-
2010
- 2010-09-01 JP JP2010195807A patent/JP5752374B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-29 US US13/482,328 patent/US8372404B2/en not_active Expired - Fee Related
-
2013
- 2013-02-05 US US13/759,687 patent/US8907072B2/en not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/551,705 patent/US20150086572A1/en not_active Abandoned
-
2016
- 2016-03-22 US US15/076,960 patent/US20160200805A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60219801D1 (de) | KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN | |
| CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
| ZA202100717B (en) | Antibody molecules that bind pd-l1 and cd137 | |
| WO2020132066A8 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof | |
| MX2023001727A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| MA31899B1 (fr) | Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant | |
| CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| MA30876B1 (fr) | Anticorps de la lymphotoxine-alpha | |
| MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
| ATE461220T1 (de) | Anti-egfr-antikörper | |
| ATE449791T1 (de) | Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung | |
| CY1111958T1 (el) | Θεραπευτικη χρηση αντισωματων anti-csi | |
| DE60226723D1 (de) | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes | |
| MA33052B1 (fr) | Variants de liaison anti-albumine sérique améliorés | |
| CY1124762T1 (el) | Αναστολεις πρωτεïνης δεσμευσης creb (cbp) | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
| MA33051B1 (fr) | Variants de liaison anti-albumine serique ameliores | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| ATE199321T1 (de) | Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen. | |
| EA202190056A1 (ru) | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ | |
| EA200401210A1 (ru) | Андрогенная фармацевтическая композиция и способ для лечения депрессии | |
| DE602007010459D1 (de) | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie | |
| EP1878441A3 (de) | Komplement-Inhibitoren, die an C5 und C5a binden, ohne die Bildung von C5b zu hemmen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1425042 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |